semaglutide risks cardiovascular outcomes align more closely with attained dose than achieved weight loss Can Semaglutide Cause Cancer? Know

In 2023 Lilly published results of its phase 2 trial for orforglipron, a once-daily oral drug which achieved up to 14.7% mean weight reduction at 36 weeks, and Pfizer has completed phase 2 trial for its oral drug danuglipron and is now optimising the formulation

Glucagon-receptor activation contributes effects on hepatic lipid metabolism and whole-body energy expenditure that are absent from GLP-1 mono-agonists and dual GLP-1/GIP agonists

Appetite suppression often occurs before measurable weight loss appears on the scale

Visual indicators A properly reconstituted and stored semaglutide solution should remain clear and colorless throughout its 28-day life

My guess is that a significant amount of the stuff coming from the compounding pharmacies is not quite Ozempic, since theres not enough of that to go around at the moment, and in some cases it may be even worse than that